Restoration of expression of transforming growth factor-β type II receptor in murine renal cell carcinoma (renca) cells by 5-Aza-2′-deoxycytidine

被引:12
|
作者
Zhang, Q [1 ]
Rubenstein, JN [1 ]
Liu, VC [1 ]
Park, I [1 ]
Jang, T [1 ]
Lee, C [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Dept Urol, Chicago, IL 60611 USA
关键词
renal cell carcinoma; TGF-beta receptors; TGF-beta signaling; promoter methylation;
D O I
10.1016/j.lfs.2004.10.021
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The murine renal cell carcinoma (Renca) cells are insensitive to TGF-beta due to a lack of TGF-beta type II receptor (TbetaR-II). The objective of the present study is to determine the mechanism of this loss of sensitivity to TGF-beta in Renca cells. Renca cells were cultured and treated with 5-Aza-2' -Deoxycytidine (5-Aza), a specific inhibitor of methylation. Expression of TGF-beta type I receptor (TbetaRI) and TbetaRII was determined by RT-PCR and Western blot analysis before and after the treatment of Renca cells with 5-Aza. The expression of phosphorylated Smad2 (P-Smad2) was determined by Western blot analysis. TGF-beta levels in the conditioned medium were measured by ELISA. Renca cells did not express TbetaR-II prior to 5-Aza treatment. After 5-Aza treatment, these cells expressed TbetaR-II at both mRNA and protein levels, which corresponded to the restoration of sensitivity to TGF-beta by an increase in P-Smad2. Levels of TGF-beta1 were similar before and after 5-Aza treatment. Results of the present study indicated that, in Renca cells, the loss of sensitivity to TGF-beta is likely due to a promoter hypermethylation in the TbetaR-II gene. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:1159 / 1166
页数:8
相关论文
共 50 条
  • [31] Mutation analysis of the transforming growth factor-β type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-β
    F Vincent
    M Nagashima
    S Takenoshita
    M A Khan
    A Gemma
    K Hagiwara
    W P Bennett
    Oncogene, 1997, 15 : 117 - 122
  • [32] Increased type II transforming growth factor-β receptor expression in liver cells during cholesterol challenge
    Baccante, G
    Mincione, G
    Di Febbo, C
    Coppa, A
    Angelucci, D
    Lapenna, D
    Cuccurullo, F
    Colletta, G
    Porreca, E
    ATHEROSCLEROSIS, 2000, 152 (01) : 51 - 57
  • [33] Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-aza-2′-deoxycytidine
    Yuan, BZ
    Jefferson, AM
    Popescu, NC
    Reynolds, SH
    NEOPLASIA, 2004, 6 (04): : 412 - 419
  • [34] 5-Aza-2′-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel by decreasing LEF1/phospho-β-catenin expression
    Shang, Donghao
    Liu, Yuting
    Xu, Xiuhong
    Han, Tiandong
    Tian, Ye
    CANCER LETTERS, 2011, 311 (02) : 230 - 236
  • [35] Relation of type II transforming growth factor-β receptor to hepatic fibrosis and hepatocellular carcinoma
    Ueno, T
    Hashimoto, O
    Kimura, R
    Torimura, T
    Kawaguchi, T
    Nakamura, T
    Sakata, R
    Koga, H
    Sata, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2001, 18 (01) : 49 - 55
  • [36] Reduction of transforming growth factor-β type II receptor is caused by the enhanced ubiquitin-dependent degradation in human renal cell carcinoma
    Fukasawa, Hirotaka
    Yamamoto, Tatsuo
    Fujigaki, Yoshihide
    Misaki, Taro
    Ohashi, Naro
    Takayama, Tatsuya
    Suzuki, Sayuri
    Mugiya, Soichi
    Oda, Toshiaki
    Uchida, Chiharu
    Kitagawa, Kyoko
    Hattori, Takayuki
    Hayashi, Hidetoshi
    Ozono, Seiichiro
    Kitagawa, Masatoshi
    Hishida, Akira
    INTERNATIONAL JOURNAL OF CANCER, 2010, 127 (07) : 1517 - 1525
  • [37] Gene expression profiling of the combined treatment with everolimus and 5-Aza-2′-deoxycytidine in medullary thyroid carcinoma cell line
    Dicitore, A.
    Gaudenzi, G.
    Persani, L.
    Vitale, G.
    WIENER KLINISCHE WOCHENSCHRIFT, 2014, 126 : S151 - S151
  • [38] Transcriptional activation of the type II transforming growth factor-β receptor gene upon differentiation of embryonal carcinoma cells
    Kelly, D
    Kim, SJ
    Rizzino, A
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (33) : 21115 - 21124
  • [39] Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells
    Veronica Bovenzi
    Richard L. Momparler
    Cancer Chemotherapy and Pharmacology, 2001, 48 : 71 - 76
  • [40] Antineoplastic action of 5-aza-2′-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor β and estrogen receptor α genes in breast carcinoma cells
    Bovenzi, V
    Momparler, RL
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2001, 48 (01) : 71 - 76